First-In-Class Pharmaceutical Therapies Nasdaq Stock

[Click to view in browser](. [Top-line data from the company’s Phase 2 trial is anticipated before the year ends…]( As baby boomers age, eye issues continue to boom. As more people spend their time on screens, eye issues continue to accelerate. The growing eye industry is something investors can’t ignore much longer. Dry eye disease is one of the most common ocular eye conditions. It’s no surprise that the market has become extensive for dry eye drugs including brand names like Novartis’ Xiidra and Allergan’s Restasis. One growing company hiding on the NASDAQ could be positioned for tremendous growth ahead as it uniquely stands out in the dry eye disease market! This company has a new chemical entity that targets BOTH ocular inflammation and corneal neuropathic pain in dry eye disease! Something that has yet to be seen for any other drug! Such a drug profile potentially opens a wide door for this underfollowed company to tap into an underserved niche market and creates the potential for shareholder growth. This is one of the most exciting times for the company as well as it moves toward initiating a Phase 2, first-in-human, clinical study of its candidate for the treatment of dry eye disease. If it is successful in hitting its clinical trial efficacy endpoints before the end of this year, the Company could be in a strong negotiating position to clinch a business development partnership and/or potentially a trade sale to a Big Pharma focused on eye diseases! [Discover why coverage of the company was initiated by Goldman Small Cap Research with a price target of $5.50!]( --------------------------------------------------------------- PLEASE NOTE: InsiderMonkey.com, InvestingChannel, Inc., and its employees are not a registered investment adviser, broker-dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. This Newsletter is operated by InvestingChannel, Inc. (“InvestingChannel”, “we” or “our”). Our website and newsletter are for entertainment purposes only. This newsletter is NOT a source of unbiased information. InvestingChannel does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services should never be construed as an endorsement of or opinion about any security. You are reading this Newsletter because you have subscribed via our Opt-In Signup form on InsiderMonkey.com (“Insider Monkey”). Insider Monkey is not affiliated with InvestingChannel. If you have been subscribed by mistake, you may unsubscribe [HERE](. If you would rather not receive free reports, email alerts, or special discounts from Insider Monkey, you can let us know by visiting [( or use the [unsubscribe link](. This is a PAID ADVERTISEMENT provided to customers/subscribers of InsiderMonkey.com. Although we have sent you this email, InsiderMonkey.com does NOT endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. IMPORTANT DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that InsiderMonkey.com and InvestingChannel are being paid on a Cost-Per-Click basis which may exceed a fee of over $1000.00 in cash, from an unaffiliated third-party (“advertiser”) as compensation for the distribution of this advertisement. InsiderMonkey.com has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertisement, is to provide publicity for the advertiser, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of securities may result in the loss of your entire investment. You understand that this advertisement or our website constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. This advertisement is not a solicitation, offer, inducement, invitation or recommendation to buy securities, services or product of the advertiser. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of the advertiser, you should call your state securities regulator to determine if the security may be sold in your state. You should read and review, if and to the extent available, any information concerning the advertiser available at the websites of the U.S. Securities and Exchange Commission (the "SEC") at and the Financial Industry Regulatory Authority (the "FINRA") at . Many companies have information filed with state securities regulators who may be able to supply you with additional information. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud available at as well as related information published by FINRA on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence. We strongly encourage you to conduct your own research before making any investment decisions. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertiser, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of external websites, nor are we responsible for the content, advertising, opinions, products or other materials on external websites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email, external website or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates, and agents harmless. You acknowledge that you are not relying on us, and we are not liable for any actions taken by you based on any information contained in any disseminated email, website or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertiser. Insider Monkey, 24 Westervelt Avenue, Tenafly, NJ, 07670 [Link](